AL Amyloidosis Market Report 2026

The al amyloidosis market size has grown rapidly in recent years. It will grow from $3.51 billion in 2025 to $3.97 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to limited treatment options, reliance on conventional chemotherapy, low disease awareness, inadequate organ-specific supportive care, minimal access to specialized treatment centers.

The al amyloidosis market size is expected to see rapid growth in the next few years. It will grow to $6.38 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to development of novel targeted therapies, increasing adoption of monoclonal antibodies and proteasome inhibitors, expansion of stem cell transplant programs, rising healthcare infrastructure for rare diseases, improved diagnostic technologies for early detection. Major trends in the forecast period include increasing adoption of targeted therapies for al amyloidosis, rising use of monoclonal antibodies and proteasome inhibitors, expansion of stem cell transplant procedures, growing focus on organ-specific supportive care, increased awareness and early diagnosis of al amyloidosis.

The increasing incidence of plasma cell disorders is expected to drive the growth of the AL amyloidosis market in the coming years. Plasma cell disorders are conditions in which abnormal plasma cells produce excessive or defective antibodies, potentially leading to organ damage. The rising occurrence of plasma cell disorders is attributed to factors such as an aging population, longer life expectancy, and advancements in diagnostic technologies. AL amyloidosis develops as a result of plasma cell disorders, specifically due to the overproduction of abnormal light chain proteins, which can accumulate as amyloid deposits in organs and tissues, worsening the effects of plasma cell dyscrasias. For instance, in August 2024, the American Cancer Society (ACS), a U.S.-based nonprofit organization, reported that approximately 35,780 new cases of multiple myeloma are expected to be diagnosed in 2024 (19,520 in men and 16,260 in women), with around 12,540 deaths projected (7,020 in men and 5,520 in women). Therefore, the rising incidence of plasma cell disorders is fueling the growth of the AL amyloidosis market.

Major companies operating in the AL amyloidosis market are focusing on developing innovative therapies, such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, to improve treatment outcomes and patient prognosis. Next-generation BCMA-directed CAR T-cell therapy is an advanced form of immunotherapy in which a patient’s T cells are engineered to target and destroy BCMA on the surface of cancer cells, particularly in multiple myeloma. For instance, in September 2023, Immix Biopharma Inc., a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for NXC-201 to treat the life-threatening blood disorder Amyloid Light Chain (AL) Amyloidosis. NXC-201, a next-generation CAR-T cell therapy, is being tested in clinical trials for AL amyloidosis and has shown promising results, including a 100% hematologic response rate and improvements in organ function among patients who had failed prior treatments.

In November 2024, Stand Up To Cancer (SU2C), a U.S.-based nonprofit organization, partnered with Johnson & Johnson Inc. to develop new treatments for AL amyloidosis. Through this collaboration, Stand Up To Cancer and Johnson & Johnson aim to advance research on the combination of teclistamab and daratumumab as a therapy for AL amyloidosis, a rare and difficult-to-treat disease, with the goal of expanding therapeutic options for affected patients. Johnson & Johnson Inc. is a U.S.-based healthcare company specializing in treatments for AL amyloidosis.

Major companies operating in the al amyloidosis market are Johnson & Johnson, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Pfizer Inc., Amgen Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Novartis AG, Merck & Co. Inc., Eli Lilly and Company, GlaxoSmithKline plc, Genmab A/S, Prothena Corporation plc, BridgeBio Pharma Inc., Oncopeptides AB, Ionis Pharmaceuticals Inc., Neurimmune AG, Immix Biopharma Inc., Attralus Inc.

North America was the largest region in the AL amyloidosis market in 2025. The regions covered in the al amyloidosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the al amyloidosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the AL Amyloidosis market by increasing costs for imported drugs, monoclonal antibodies, proteasome inhibitors, and stem cell transplant-related equipment. Hospital pharmacies and retail pharmacies in regions like north america, europe, and asia-pacific are most affected by these tariffs, leading to higher treatment costs and delayed patient access. On the positive side, tariffs have encouraged local production of specialty drugs and innovation in domestic treatment options, which may enhance long-term availability and affordability.

The al amyloidosis market research report is one of a series of new reports that provides al amyloidosis market statistics, including al amyloidosis industry global market size, regional shares, competitors with a al amyloidosis market share, detailed al amyloidosis market segments, market trends and opportunities, and any further data you may need to thrive in the al amyloidosis industry. This al amyloidosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

AL Amyloidosis is a rare and serious disorder in which abnormal proteins, known as light chains, are produced by plasma cells in the bone marrow. These light chains misfold and form amyloid fibrils, which accumulate in various organs and tissues, impairing their function. Commonly affected organs include the heart, kidneys, liver, and nervous system. Symptoms vary depending on the organs involved and may include fatigue, swelling, shortness of breath, numbness, and organ dysfunction.

The primary treatments for AL amyloidosis include a range of therapies such as chemotherapy, supportive care, surgery, stem cell transplant, and targeted therapy. Chemotherapy involves potent drugs that target amyloid deposits with the goal of reducing symptoms and improving survival. These drugs include transthyretin transport inhibitors, immunomodulatory drugs, monoclonal antibodies, and proteasome inhibitors, and can be administered orally or intravenously. Regarding distribution, these medications are typically accessible through hospital pharmacies, retail pharmacies, and online pharmacies, providing patients with options based on their needs and convenience.

The AL amyloidosis market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, monitoring and follow-up services, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The AL amyloidosis market also includes sales of proteasome inhibitors, monoclonal antibodies, diagnostic tests, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.